fig2
Figure 2. Level of Evidence for drug-based HCC chemoprevention. Semi-quantitative graphical summary of the relative strength of evidence supporting statins, aspirin, metformin, semaglutide, ARBs, lanifibranor, resmetirom, ACE inhibitors, and aripiprazole as candidate approaches for HCC chemoprevention. ACE: Angiotensin-converting enzyme; ARBs: angiotensin II receptor blockers; HCC: hepatocellular carcinoma.
